Association of transplant variables with the recovery of T-cell subsets and function
| Variable . | CD4+ T cells . | CD4+CD45RA+ T cells . | CD8+ T cells . | PHA . | ||||
|---|---|---|---|---|---|---|---|---|
| Slope (95% CI) . | P . | Slope (95% CI) . | P . | Slope (95% CI) . | P . | Slope (95% CI) . | P . | |
| Age (10 y) | −0.09 (−0.20, 0.01) | .087 | −0.05 (−0.22, 0.12) | .539 | 0.01 (−0.15, 0.16) | .924 | −0.08 (−0.21, 0.04) | .205 |
| 8-allele HLA-match* | .200 | .545 | .105 | .565 | ||||
| <5/8 | reference | reference | reference | reference | ||||
| ≥5/8 | 0.19 (−0.10, 0.47) | 0.14 (−0.30, 0.58) | −0.33 (−0.73, 0.07) | 0.09 (−0.22, 0.41) | ||||
| Infused viable CD34+cell dose* | .646 | .333 | .245 | .574 | ||||
| <1.18 × 105/kg | reference | reference | reference | reference | ||||
| ≥1.18 × 105/kg | −0.06 (−0.32, 0.20) | −0.20 (−0.60, 0.20) | 0.22 (−0.15, 0.58) | 0.08 (−0.21, 0.37) | ||||
| Infused viable CD3+cell dose* | .045 | .020 | .893 | .065 | ||||
| <3.34 × 106/kg | reference | reference | reference | reference | ||||
| ≥3.34 × 106/kg | 0.26 (0.01, 0.52) | 0.47 (0.08, 0.87) | 0.03 (−0.34, 0.39) | 0.27 (−0.01, 0.56) | ||||
| CMV reactivation by day 60 | .005 | .171 | <.001 | <.001 | ||||
| No CMV reactivation | reference | Reference | reference | reference | ||||
| CMV reactivation | −0.39 (−0.66, −0.13) | −0.31 (−0.75, 0.13) | 1.15 (0.77, 1.52) | −0.58 (−0.86, −0.29) | ||||
| Day 100 aGVHD grade | .651 | .386 | .630 | .435 | ||||
| 0-I | reference | reference | reference | reference | ||||
| II | −0.16 (−0.52, 0.20) | −0.05 (−0.62, 0.51) | 0.29 (−0.32, 0.90) | −0.20 (−0.61, 0.21) | ||||
| III-IV | −0.19 (−0.65, 0.27) | 0.37 (0.36, 1.10) | 0.30 (−0.48, 1.07) | −0.33 (−0.83, 0.17) | ||||
| Variable . | CD4+ T cells . | CD4+CD45RA+ T cells . | CD8+ T cells . | PHA . | ||||
|---|---|---|---|---|---|---|---|---|
| Slope (95% CI) . | P . | Slope (95% CI) . | P . | Slope (95% CI) . | P . | Slope (95% CI) . | P . | |
| Age (10 y) | −0.09 (−0.20, 0.01) | .087 | −0.05 (−0.22, 0.12) | .539 | 0.01 (−0.15, 0.16) | .924 | −0.08 (−0.21, 0.04) | .205 |
| 8-allele HLA-match* | .200 | .545 | .105 | .565 | ||||
| <5/8 | reference | reference | reference | reference | ||||
| ≥5/8 | 0.19 (−0.10, 0.47) | 0.14 (−0.30, 0.58) | −0.33 (−0.73, 0.07) | 0.09 (−0.22, 0.41) | ||||
| Infused viable CD34+cell dose* | .646 | .333 | .245 | .574 | ||||
| <1.18 × 105/kg | reference | reference | reference | reference | ||||
| ≥1.18 × 105/kg | −0.06 (−0.32, 0.20) | −0.20 (−0.60, 0.20) | 0.22 (−0.15, 0.58) | 0.08 (−0.21, 0.37) | ||||
| Infused viable CD3+cell dose* | .045 | .020 | .893 | .065 | ||||
| <3.34 × 106/kg | reference | reference | reference | reference | ||||
| ≥3.34 × 106/kg | 0.26 (0.01, 0.52) | 0.47 (0.08, 0.87) | 0.03 (−0.34, 0.39) | 0.27 (−0.01, 0.56) | ||||
| CMV reactivation by day 60 | .005 | .171 | <.001 | <.001 | ||||
| No CMV reactivation | reference | Reference | reference | reference | ||||
| CMV reactivation | −0.39 (−0.66, −0.13) | −0.31 (−0.75, 0.13) | 1.15 (0.77, 1.52) | −0.58 (−0.86, −0.29) | ||||
| Day 100 aGVHD grade | .651 | .386 | .630 | .435 | ||||
| 0-I | reference | reference | reference | reference | ||||
| II | −0.16 (−0.52, 0.20) | −0.05 (−0.62, 0.51) | 0.29 (−0.32, 0.90) | −0.20 (−0.61, 0.21) | ||||
| III-IV | −0.19 (−0.65, 0.27) | 0.37 (0.36, 1.10) | 0.30 (−0.48, 1.07) | −0.33 (−0.83, 0.17) | ||||
Engrafting CB unit.
There was no association with the variables of recipient sex, diagnosis (acute leukemia vs MDS/MPD vs lymphoma), or the addition of haploidentical CD34+ cells (data not shown). P values significant at the .01 level are indicated in bold.